Resmed (RMD) Cash & Equivalents (2009 - 2026)

Resmed (RMD) has 18 years of Cash & Equivalents data on file, last reported at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 78.03% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 78.03% YoY), and the FY2025 full-year result was $1.2 billion, up 407.4% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.7 billion, up from $1.4 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q1 2026 and bottomed at $201.8 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $253.2 million (2022), against an average of $578.8 million.
• The widest annual swing landed in 2022, when Cash & Equivalents decreased 24.98%; it then soared 407.4% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $253.2 million in 2022, then dropped by 16.96% to $210.2 million in 2023, then jumped by 148.25% to $521.9 million in 2024, then soared by 171.5% to $1.4 billion in 2025, then rose by 17.18% to $1.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.7 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison